乌帕替尼与阿达木单抗在心血管疾病风险较高或较低的类风湿关节炎患者中的获益-风险分析
基于SELECT-COMPARE研究的事后分析,按心血管风险分层比较乌帕替尼15 mg与阿达木单抗40 mg(均联用甲氨蝶呤)在甲氨蝶呤应答不足的类风湿关节炎患者中的安全性与疗效。低风险组211例(乌帕替尼129例、阿达木单抗82例),高风险组767例(乌帕替尼522例、阿达木单抗245例)。两组恶性肿瘤(除外非黑色素瘤皮肤癌)、主要不良心血管事件和静脉血栓栓塞发生率相当,但高风险组数值更高;乌帕替尼在两个风险组带状疱疹发生率均更高,高风险组严重感染和非黑色素瘤皮肤癌数值更高;乌帕替尼疗效持续更优。
要点
- 低风险组211例(乌帕替尼129例、阿达木单抗82例),高风险组767例(乌帕替尼522例、阿达木单抗245例)。
- 两组恶性肿瘤(除外非黑色素瘤皮肤癌)、主要不良心血管事件和静脉血栓栓塞发生率相当,高风险组数值更高。
- 乌帕替尼两个风险组带状疱疹发生率均更高,高风险组严重感染和非黑色素瘤皮肤癌数值更高。
核心结论
- 无论基线心血管风险如何,乌帕替尼安全性除带状疱疹(两个风险组均更高)及高风险组非黑色素瘤皮肤癌和严重感染外与阿达木单抗相当。
- 乌帕替尼在临床和功能结局上持续优于阿达木单抗,其获益-风险特征在短期和长期均有利,且不依赖心血管风险分层。
研究设计与样本
- SELECT-COMPARE研究的事后分析,患者接受乌帕替尼15 mg、安慰剂或阿达木单抗40 mg每两周一次,均联用甲氨蝶呤。
- 按心血管风险分层:低风险(年龄<65岁且无心血管危险因素)与高风险(年龄≥65岁和/或≥1个心血管危险因素)。
- 基于心血管风险比较乌帕替尼与阿达木单抗短期(约6个月)和长期(5年)的安全性与疗效结局。
主要发现
- 低风险组211例(乌帕替尼129例、阿达木单抗82例),高风险组767例(乌帕替尼522例、阿达木单抗245例)。
- 两组恶性肿瘤(除外非黑色素瘤皮肤癌)、主要不良心血管事件和静脉血栓栓塞发生率相当,但高风险组数值更高。
- 乌帕替尼两个风险组带状疱疹发生率均高于阿达木单抗,高风险组严重感染和非黑色素瘤皮肤癌数值更高。
- 乌帕替尼在6个月时28关节疾病活动度评分(C反应蛋白)<2.6、临床疾病活动指数缓解和布尔缓解等疗效结局持续更优,并基本维持至5年。
关键数值与推荐
- 低风险定义:年龄<65岁且无心血管危险因素;高风险定义:年龄≥65岁和/或≥1个心血管危险因素。
- 疗效评估指标包括28关节疾病活动度评分(C反应蛋白)<2.6、临床疾病活动指数缓解和布尔缓解,评估时间点为6个月并随访至5年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Evaluate the risks and benefits of upadacitinib 15 mg vs adalimumab in rheumatoid arthritis (RA) patients with an inadequate response to methotrexate based on cardiovascular (CV) risk. METHODS: In SELECT-COMPARE, patients received upadacitinib 15 mg, placebo or adalimumab 40 mg every other week, with background methotrexate. This post hoc analysis assessed patients with lower (age <65 years; no CV risk factors) and higher CV risk (age ≥65 years and/or ≥1 CV risk factor). Safety and efficacy outcomes were compared between upadacitinib and adalimumab over the short term (~6 months) and long term (5 years) based on CV risk. RESULTS: The study included 211 lower-risk patients (upadacitinib, n=129; adalimumab, n=82) and 767 higher-risk patients (upadacitinib, n=522; adalimumab, n=245). Rates of malignancy excluding nonmelanoma skin cancer (NMSC), major adverse cardiovascular event and venous thromboembolism were comparable between upadacitinib and adalimumab in both risk groups but numerically higher in the higher-risk group. Upadacitinib showed higher rates of herpes zoster versus adalimumab in both risk groups and numerically higher rates of serious infection and NMSC in the higher-risk group. Upadacitinib demonstrated consistently better efficacy outcomes, including 28-joint Disease Activity Score (C reactive protein) <2.6, Clinical Disease Activity Index remission and Boolean remission at 6 months, which were generally maintained through 5 years. CONCLUSIONS: Regardless of baseline CV risk, upadacitinib demonstrated comparable safety to adalimumab, except for higher rates of herpes zoster in both CV risk groups and NMSC and serious infections in the higher-risk group. Upadacitinib consistently showed better clinical and functional outcomes than adalimumab. The benefit-risk profile of upadacitinib in RA patients was favourable, independent of CV risk category, in both short and long term.
引用
- Burmester GR, Mysler E, Taylor P, et al. Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease. RMD Open. 2025. PMID: 40461266. doi:10.1136/rmdopen-2024-005371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。